Aurinia Pharmaceuticals (AUPH) Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. SPY
5. ACN
6. IBM
7. PRIM
8. PFE
9. TSLA
10. DPZ

Go back to Aurinia Pharmaceuticals (AUPH) Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis

Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 6c

November 3, 2021 6:05 AM EDT

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $13.88 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2021 revenue of $40-50 million, versus the consensus of... More